Risk factors for progression in MPNs

Автор: VJHemOnc – Video Journal of Hematology & HemOnc

Загружено: 2020-08-28

Просмотров: 278

Описание: Andrew Kuykendall, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses factors that predict progression in myeloproliferative neoplasms, including clinical and genetic characteristics that can result in acute leukemia development. Dr Kuykendall also highlights the role of inflammatory cytokines that have been implicated in the development of MPNs. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Не удается загрузить Youtube-плеер. Проверьте блокировку Youtube в вашей сети.
Повторяем попытку...

Risk factors for progression in MPNs

Доступные форматы для скачивания:

Скачать видео

Информация по загрузке:

Скачать аудио

Похожие видео

Risk Factors for Disease Progression in Patients with Polycythemia Vera

Risk Factors for Disease Progression in Patients with Polycythemia Vera

Myeloproliferative Neoplasms (MPN) Treatment: Polycythema Vera (PV) & Essential Thrombocythemia (ET)

Myeloproliferative Neoplasms (MPN) Treatment: Polycythema Vera (PV) & Essential Thrombocythemia (ET)

Sustained Remission in Hard-to-Treat Crohn’s: Insights From SEQUENCE

Sustained Remission in Hard-to-Treat Crohn’s: Insights From SEQUENCE

Meeting the Many Challenges of Uncontrolled Polycythemia Vera

Meeting the Many Challenges of Uncontrolled Polycythemia Vera

Risk factors for progression in MPNs

Risk factors for progression in MPNs

ASH 2025 Expert Insights: New Approach to CALR-Mutant Myelofibrosis

ASH 2025 Expert Insights: New Approach to CALR-Mutant Myelofibrosis

What are the key considerations in managing pregnancy in MPN?

What are the key considerations in managing pregnancy in MPN?

Behind the Mystery: Living with Polycythemia Vera

Behind the Mystery: Living with Polycythemia Vera

Identifying risk factors for thrombosis in MPNs and treatment strategies

Identifying risk factors for thrombosis in MPNs and treatment strategies

30 Years of Business Advice in 13 Minutes (from a Billionaire)

30 Years of Business Advice in 13 Minutes (from a Billionaire)

An Overview of ET, PV and MF Treatment Options

An Overview of ET, PV and MF Treatment Options

Deferasirox - Dr. Sandra Loggetto

Deferasirox - Dr. Sandra Loggetto

Monitoring Progression: Mitigating Risk in MPN Patients

Monitoring Progression: Mitigating Risk in MPN Patients

Hematology | Polycythemias

Hematology | Polycythemias

Бактериальная генетика

Бактериальная генетика

Indication for cytoreductive therapy in ET and PV: Do we have it right?

Indication for cytoreductive therapy in ET and PV: Do we have it right?

The 20-Year-Old Cholesterol Study Everyone Missed

The 20-Year-Old Cholesterol Study Everyone Missed

What are Myeloproliferative Neoplasms? For Patients & Caregivers from Top MPN Specialist

What are Myeloproliferative Neoplasms? For Patients & Caregivers from Top MPN Specialist

Prognostication and initiation of therapy in Polycythemia vera: Do we have it right?

Prognostication and initiation of therapy in Polycythemia vera: Do we have it right?

PV: outcomes, unmet needs, and therapeutic strategies

PV: outcomes, unmet needs, and therapeutic strategies